Neuroendocrine Tumor Clinical Trial
The purpose of this study is to determine if the measurement (with a standard nuclear
camera) of radioactivity normally present in the nervous system of your heart at four hours
after the injection of radioactive drug for your diagnostic I-123 MIBG scan is any different
than radioactivity measured in your heart at one and/or two hours after your diagnostic scan
injection. If equivalent information to the conventional 4 hr H/M ratio could be collected
by obtaining H/M ratios at 1 or 2 hour windows, it would greatly facilitate patient
acceptance of the procedure since the requirements for obtaining a valid H/M ratio would be
considerably less time-consuming.
One hour before being injected with the drug (I-123 MIBG) for your MIBG scan, you will be
given a standard dose of non-radioactive iodine (Lugol's solution) to block your thyroid
from receiving the small amount of radiation that is a normal part of the MIBG scan. You
will then be injected with MIBG, and you will have 10 minute pictures of your chest at 15
minutes, 1 hour, 2 hours, and 4 hours in addition to the standard 24 hour pictures. These
pictures will be taken in the Nuclear Medicine Section, Department of Radiology at Ochsner
Medical Center-Kenner. The experimental (research) part of this study is having the extra
10-minute pictures of your chest at 15 minutes, 1 hour, 2 hours, and 4 hours. Normally,
pictures are only taken 24 hours after the injection. Therefore the research is limited to
the four extra pictures taken, and involve no additional injections or I-123 drug beyond
that you will be receiving regardless of whether you are part of this research.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04837885 -
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
|
Phase 2 | |
Completed |
NCT00789841 -
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
|
N/A | |
Recruiting |
NCT05069220 -
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
|
Early Phase 1 | |
Completed |
NCT05816720 -
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
|
||
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT01849523 -
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study
|
N/A | |
Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02092714 -
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
|
||
Terminated |
NCT04073017 -
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
|
N/A | |
Completed |
NCT00434109 -
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
|
Phase 2 | |
Completed |
NCT02472678 -
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor
|
N/A | |
Completed |
NCT02481804 -
Optimal Feeding for NET Patients
|
N/A | |
Completed |
NCT02147106 -
Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
|
||
Completed |
NCT00165230 -
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03012789 -
Surgical Intervention and the NETest
|
N/A | |
Not yet recruiting |
NCT02038738 -
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT00227617 -
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
|
Phase 2/Phase 3 | |
Terminated |
NCT02177773 -
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
|
Phase 1/Phase 2 |